on a reported basis in the quarter, earnings per share was $num-one, as compared to $num-two in the prior year.
adjusted earnings per share for the quarter was $num-one, a num-two% increase over the prior-year amount of $num-three.
for the full-year year-four, we exceeded $num-one billion in sales and achieved num-two% growth in local currency.
on a u.s. dollar basis, total sales increased num-one% as currencies reduced sales growth by approximately num-two% in the quarter.
by region for the year, sales increased num-one% in the americas, num-two% in europe and num-one% in asia/rest of world.
sg&a amounted to $num-one million, a num-two% increase in local currency over the prior year.
excluding the impact of the retail decline and adjusting our guidance for the estimated coronavirus impact, we would have expected sales growth in qtr-one to be in the range of num-one% to num-two%.
overall, we expect good growth in our laboratory business in year-five, although we faced more challenging comparisons after several years of very strong growth.
we again faced meaningful headwinds in the quarter due to adverse currency and impact of tariffs.
we expect the coronavirus to significantly impact sales in china in the first quarter due to the loss of selling days.
based on market conditions today, we expect local currency sales growth to be approximately num-one% to num-two%.
we would expect that adjusted earnings per share in the first quarter to be in the range of $num-one to $num-two, a growth rate of num-three% to num-four%.
we remain cautious on the macroeconomic environment as certain indicators are weak.
sales were $num-one million in the quarter, an increase of num-two% in local currency.